dc.contributor.author
Gül-Klein, Safak
dc.contributor.author
Hegermann, Henriette
dc.contributor.author
Röhle, Robert
dc.contributor.author
Schmelzle, Moritz
dc.contributor.author
Tacke, Frank
dc.contributor.author
Schöning, Wenzel
dc.contributor.author
Öllinger, Robert
dc.contributor.author
Dziodzio, Tomasz
dc.contributor.author
Maier, Patrick
dc.contributor.author
Plewe, Julius
dc.contributor.author
Horst, David
dc.contributor.author
Sauer, Igor Maximilian
dc.contributor.author
Pratschke, Johann
dc.contributor.author
Lachmann, Nils
dc.contributor.author
Eurich, Dennis
dc.date.accessioned
2021-10-15T12:14:13Z
dc.date.available
2021-10-15T12:14:13Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/32331
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-32056
dc.description.abstract
Background: Donor-specific antibodies (DSA) against donor human leukocyte antigen after liver transplantation, which are associated with histological changes, have been widely studied with respect to their sustained impact on transplant function. However, their long-term impact after liver transplantation remains unclear.
Methods: We performed a cross-sectional analysis from June 2016 to July 2017 that included all patients who presented themselves for scheduled follow-up after receiving a liver transplantation between September 1989 and December 2016. In addition to a liver protocol biopsy, patients were screened for human leukocyte antigen antibodies (HLAab) and donor-specific antibodies. Subsequently, the association between human leukocyte antigen antibodies, donor-specific antibodies, histologic and clinical features, and immunosuppression was analyzed.
Results: Analysis for human leukocyte antigen antibodies and donor-specific antibodies against donor human leukocyte antigen was performed for 291 and 271 patients. A significant association between higher inflammation grades and the presence of human leukocyte antigen antibodies and donor-specific antibodies was detected, while fibrosis stages remained unaffected. These results were confirmed by multivariate logistic regression for inflammation showing a significant increase for presence of human leukocyte antigen antibodies and donor-specific antibodies (OR: 4.43; 95% CI: 1.67-12.6; p=0.0035). Furthermore, the use of everolimus in combination with tacrolimus was significantly associated with the status of negative human leukocyte antigen antibodies and donor-specific antibodies. Viral etiology for liver disease, hepatocellular carcinoma (HCC) and higher steatosis grades of the graft were significantly associated with a lower rate of human leukocyte antigen antibodies. The impact of human leukocyte antigen antibodies and donor-specific antibodies against donor human leukocyte antigen was associated with higher levels of laboratory parameters, such as transaminases and bilirubin.
Conclusion: Donor-specific antibodies against donor human leukocyte antigen are associated with histological and biochemical graft inflammation after liver transplantation, while fibrosis seems to be unaffected. Future studies should validate these findings for longer observation periods and specific subgroups.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/3.0/
dc.subject
human leukocyte antigen antibodies
en
dc.subject
donor-specific antibodies
en
dc.subject
liver biopsy
en
dc.subject
liver transplantation
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.2147/jir.s307778
dcterms.bibliographicCitation.journaltitle
Journal of Inflammation Research
dcterms.bibliographicCitation.originalpublishername
Dove Medical Press
dcterms.bibliographicCitation.pagestart
2697
dcterms.bibliographicCitation.pageend
2712
dcterms.bibliographicCitation.volume
14
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34188517
dcterms.isPartOf.eissn
1178-7031